We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

zaterdag 2 september 2017

The Lancet: [Department of Error] Department of Error

[Department of Error] Department of Error
Mintz GS, Guagliumi G. Intravascular imaging in coronary artery disease. Lancet 2017; 390: 793–809—In the margin information of this Series paper, the corresponding email should read gmintz@crf.org. This correction has been made to the online version as of Aug 29, 2017.
Read more

[Comment] The triumph of HIV treatment: another new antiretroviral
Since the approval of the first integrase strand inhibitor (INSTI) raltegravir for the treatment of HIV 10 years ago, INSTIs have become agents of choice in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) in many international guidelines.1,2 This was driven by the sound real-world experience of this antiretroviral class, especially following the introduction of the most recently licensed INSTI, dolutegravir.
Read more

[Articles] Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
At 48 weeks, coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virological suppression in 92% of previously untreated adults and was non-inferior to coformulated dolutegravir, abacavir, and lamivudine, with no treatment-emergent resistance. Bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated with better gastrointestinal tolerability than dolutegravir, abacavir, and lamivudine. Because coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not require HLA B*5701 testing and provides guideline-recommended treatment for individuals co-infected with HIV and hepatitis B, this regimen might lend itself to rapid or same-day initiation of therapy in the clinical setting.
Read more

[Articles] Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
At 48 weeks, virological suppression with the bictegravir regimen was achieved and was non-inferior to the dolutegravir regimen in previously untreated adults. There was no emergent resistance to either regimen. The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated compared with the dolutegravir regimen.
Read more

[Comment] Stretching the carotid sinus to treat resistant hypertension
Around a quarter of adults have hypertension, and by 2025, the number affected might be more than 1·5 billion people worldwide.1 Despite important advances in pharmacotherapy in the past 40 years, resistant hypertension—that is, persistently raised ambulatory blood pressure despite treatment with at least three antihypertensive drugs, including a diuretic—occurs in about 13% of treated adults.2 Optimisation of treatment is crucial in people with resistant hypertension because of the increased risk of cardiovascular disease.
Read more